A SINGLE ORAL ASCENDING DOSE STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF RO6836191 IN HEALTHY MALE VOLUNTEERS INCLUDING A SINGLE INTRAVENOUS DOSE OF RO6836191

Completed

• Conditions: cardiovascular diseases; high blood pressure; 10019280; 10057166

• Registration Number: NL-OMON40173
• Lead Sponsor: Hoffmann-La Roche

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 29 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 96

Inclusion Criteria

18 to 45 years of age, inclusive
BMI between 18 to 30 kg/m2 inclusive
healthy male volunteers

Exclusion Criteria

suffering from hepatitis B, hepatitis C or HIV/AIDS
donation of blood over 450 mL within three months prior to screening
Participation in another investigational drug or device study within 3 months prior to dosing

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>safety and tolerability<br /><br>pharmacokinetics of oral dosing<br /><br>pharmacodynamics</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>pharmacokinetics after IV dosing</p><br>